Cresset Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cresset Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,583	Closed	-$213K	–	2187
2024 Q2	$213K	Sell	2,583 -69	-3%	-$5.74K	﹤0.01%	1872
2024 Q1	$232K	Sell	2,652 -1,898	-42%	-$170K	﹤0.01%	1699
2023 Q4	$439K	Buy	4,550 +942	+26%	+$83.3K	﹤0.01%	1292
2023 Q3	$319K	Buy	3,608 +101	+3%	+$8.99K	﹤0.01%	1417
2023 Q2	$304K	Buy	+3,507	New	+$330K	﹤0.01%	1515
2022 Q1	–	Sell	-2,996	Closed	-$265K	–	1009
2021 Q4	$265K	Buy	+2,996	New	+$247K	﹤0.01%	929
2019 Q2	–	Sell	-208	Closed	-$18K	–	628
2019 Q1	$18K	Buy	208 +75	+56%	+$6.95K	﹤0.01%	1036
2018 Q4	$11K	Buy	+133	New	+$12.7K	﹤0.01%	830

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Cresset Asset Management's BMRN Position: Q3 2024 in Review

Cresset Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 2,583 shares — an estimated $213K sold.

Cresset Asset Management first reported a position in BMRN in Q4 2018 and held it in 8 quarters. The position peaked at $439K in Q4 2023. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Cresset Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Cresset Asset Management sold 2,583 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $213K.
Cresset Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 8 quarters.
Cresset Asset Management's BioMarin Pharmaceuticals position peaked at $439K in Q4 2023.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Cresset Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.